Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Summary

In 2014, an estimated 7,000 patients were diagnosed of melanoma in China. It is growing at an annual rate of 3%-5% and approximately 20,000 new cases are reported each year recently.To date, CFDA only approved dacarbazine as first line chemotherapy and anti-PD-1 antibody monotherapy as second line. There is no standard of care after chemotherapy and anti-PD-1.

Timeline

Start

2021-11

Primary completion

2023-09

Completion

2023-09

Drugs

Indications